Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease

Distler, Oliver; B. Highland, Kristin; Gahlemann, Martina; Azuma, Arata; Fischer, Aryeh; D. Mayes, Maureen; Raghu, Ganesh; Sauter, Wiebke; Girard, M; Alves, Margarida; Clerisme-Beaty, Emmanuelle; Stowasser, Susanne; Tetzlaff, Kay; Kuwana, Masataka; M. Maher, Toby

doi:10.1056/nejmoa1903076

Public

Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease

Published in New England Journal of Medicine • May 20, 2019

Authors:

Oliver Distler

Kristin B. Highland

Martina Gahlemann

Abstract

BACKGROUND: Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis and a leading cause of systemic sclerosis-related death. Nintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects in preclinical models of systemic sclerosis a...

Subject

Nintedanib

Interstitial lung disease

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!